SLC2A1 and head and neck squamous cell carcinoma: Nonetheless, BAY-876, a novel high-affinity GLUT1 inhibitor [29], inhibits glucose uptake and viability in HNSCC cells independent of GLUT1 Golgi vs plasma membrane localization.